Products

Daniel Alain Life Science is dedicated to research and development of breakthrough drugs, devices, and natural treatments for hair loss, hair thinning, and hair shedding.

We recently licensed a breakthrough patented natural treatment for hair shedding developed by Professor Dr, Andy Goren from the University of Rome, Italy and Applied Biology in Irvine, California. We plan to introduce this innovate treatment to in early 2017.

New

Revolutionary Anti-Hair Pulling Treatment

Unexplained, excessive hair shedding can be frightening. But now a solution to prevent this is about to turn the hair loss market on its head. The average person loses between 50 and 100 strands of hair a day, and in some cases up to 150 strands. With almost 150,000 hairs on your head, that's still less than 1%. Although shedding is a normal part of the hair’s cycle, Daniel Alain Life Science is focused on preventing hair pulling with a new treatment that dramatically reduces shedding in women by increasing the force holding the follicle to the scalp, thus less hair on your hairbrush. The Sinclair Shedding Scale, developed by Professor Rodney Sinclair, an Australian dermatologist, indicates the scalable severity of a woman’s hair shedding. Sinclair’s hypothesis states that excessive shedding could further develop into female pattern hair loss. In a hospital survey of 300 women, approx. 40% who did not suffer from female-pattern hair loss reported excessive shedding on days they wash their hair, while only 9% reported excessive shedding on days they did not wash their hair. A new scalp and hair treatment from Daniel Alain aims to reduce shedding from a five or six on the scale to a four or below, with the goal of bringing it down to a one or two. This groundbreaking treatment will be available nationwide in the USA soon.

Contact us for more information
6 5 4 3 2 1
Minoxidil Sensitivity Test (for men and women)

Revolutionary Anti-Hair Pulling Treatment

Following 24 weeks of treatment, topical minoxidil is effective in re-growing hair in approximately 30%-40% of women. Due to the long treatment time and low response rate it is of great clinical importance to identify patients that will not benefit from topical minoxidil. The revolutionary Daniel Alain Minoxidil Sensitivity test informs a patient prior to starting therapy whether or not they will be a responder to 5% Topical Minoxidil. The in vitro diagnostic test is conducted at the doctor’s office. The Daniel Alain Minoxidil sensitivity test is currently available in Europe and we are currently working toward gaining approval in the United States.

Contact us for more information